New treatment approach for T-cell cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter observational study aims to identify innovative strategies to selectively eliminate malignant T cells by modulating intracellular reactive oxygen species (ROS) levels. It will investigate the interactions between drugs that activate apoptosis, such as Venetoclax, and those that alter ROS homeostasis, like glucose-6-phosphate dehydrogenase inhibitors. The most promising compounds will be selected based on in vitro results from cell lines and patient-derived xenografts (PDX), and subsequently tested ex vivo on cells from patients with resistant or refractory T-cell neoplasms.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with pre- and post-thymic T-cell leukemia/lymphoma
* Patients of both sexes
* Age of patients older than 18 years
* Patient is willing to provide written and signed informed consent for participation in the study

Exclusion Criteria:

-Serious illness or medical condition that does not allow the patient to be managed according to standard treatment protocols, including uncontrolled active infection.

Where it's running

• Istituto Nazionale Tumori Fondazione G.Pascale
  Naples, Italy Recruiting
• Istituto Oncologico Veneto
  Padova, Italy Recruiting

Study contacts

• Study coordinator: Michele Gottardi, MD
• Email: michele.gottardi@iov.veneto.it
• Phone: +39 0423732336

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Preventing Adult T-cell Leukemia/Lymphoma in People with HTLV-1

  This study is testing if a new drug called mogamulizumab can help prevent adult T-cell leukemia/lymphoma in adults who are infected with the HTLV-1 virus and are at higher risk for this cancer.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06698003

• Lobular Breast Cancer with Low or No Hormone Receptors: Real-World International Cohort

  This study tests how hormone receptor–negative/low lobular breast cancer behaves in real-world patients by collecting data from multiple centers.

  Recruiting Istituto Oncologico Veneto IRCCS · Padova · NCT07613151

• Virtual reality to reduce pain and anxiety during outpatient urology procedures

  This trial will try a virtual reality headset (REALICA®) to reduce pain and anxiety for adults having outpatient urology procedures such as circumcision, prostate biopsy, or flexible cystoscopy.

  Recruiting Istituto Oncologico Veneto IRCCS · Padova · NCT07338292

• Preventing wound complications after limb sarcoma surgery with a single-use negative-pressure dressing

  This test will try a single-use negative-pressure wound dressing (PICO14) to see if it reduces wound complications after limb high-grade soft tissue sarcoma surgery in adults who received preoperative radiotherapy.

  Recruiting Istituto Oncologico Veneto IRCCS · Padova, Italy/Padova · NCT06941194

• Advanced breast surgery techniques for better outcomes

  This study is testing new breast surgery techniques to see if they can improve cancer treatment results and the appearance of the breast for patients with early-stage breast cancer.

  Recruiting Istituto Oncologico Veneto IRCCS · Padova · NCT06906237

• Electrochemotherapy for unresectable visceral tumors including liver metastases

  This will try electrochemotherapy with bleomycin in adults who have unresectable primary or metastatic visceral tumors, such as liver metastases.

  Recruiting Istituto Oncologico Veneto IRCCS · Padova · NCT06753136

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.